{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:40:44Z","timestamp":1761946844178,"version":"3.44.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.yjmcc.2020.06.007","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T21:30:07Z","timestamp":1592429407000},"page":"84-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Apelin-potential therapy for COVID-19?"],"prefix":"10.1016","volume":"145","author":[{"given":"Seyed Soheil","family":"Saeedi Saravi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrg H.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yjmcc.2020.06.007_bb0005","article-title":"Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus","volume":"6","author":"Gu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0015","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme","volume":"275","author":"Tipnis","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41581-020-0279-4","article-title":"Controversies of renin\u2013angiotensin system inhibition during the COVID-19 pandemic","author":"South","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-017-1882-z","article-title":"Recombinant human ACE2: acing out angiotensin II in ARDS therapy","volume":"21","author":"Zhang","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0035","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.HYP.0000193538.20705.23","article-title":"The prothrombotic paradox of hypertension","volume":"46","author":"Dielis","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0040","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCULATIONAHA.109.911339","article-title":"Acute cardiovascular effects of Apelin in humans","volume":"121","author":"Japp","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30224-1","article-title":"SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors","author":"Milne","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)","author":"Mehta","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1863","article-title":"Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence","author":"Sriram","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0060","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic","author":"Driggin","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.yjmcc.2020.06.007_bb0065","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1172\/JCI69608","article-title":"Apelin is a positive regulator of ACE2 in failing hearts","volume":"123","author":"Sato","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0070","series-title":"The Apelin-APJ axis is an endogenous counterinjury mechanism in experimental acute lung injury","first-page":"969","volume":"147(4)","author":"Fan","year":"2015"},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0075","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.tips.2015.06.002","article-title":"Apelin, Elabela\/toddler, and biased agonists as novel therapeutic agents in the cardiovascular system","volume":"36","author":"Yang","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.yjmcc.2020.06.007_bb0080","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/HJH.0b013e32834347de","article-title":"Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases PAI-1 production","volume":"29","author":"Siddiquee","year":"2011","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.yjmcc.2020.06.007_bb0085","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/13813455.2018.1453521","article-title":"Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats","volume":"125","author":"Sabry","year":"2019","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0090","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-020-03461-7","article-title":"Apelin\/APJ system: an emerging therapeutic target for respiratory diseases","author":"Yan","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0095","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa254","article-title":"Acute pulmonary embolism and COVID-19 pneumonia: a random association?","author":"Danzi","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0100","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/HYPERTENSIONAHA.114.05099","article-title":"Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist","volume":"65","author":"Brame","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.yjmcc.2020.06.007_bb0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcp.2016.07.018","article-title":"Cardiac action of the first G protein biased small molecule apelin agonist","volume":"116","author":"Read","year":"2016","journal-title":"Biochem. Pharmacol."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282820302169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282820302169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T20:30:46Z","timestamp":1758313846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282820302169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":20,"alternative-id":["S0022282820302169"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2020.06.007","relation":{},"ISSN":["0022-2828"],"issn-type":[{"type":"print","value":"0022-2828"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apelin-potential therapy for COVID-19?","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2020.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}